Acute myeloid leukaemia with recurrent genetic abnormalities

• Acute myeloid leukaemia with t(8;21)(q22;q22), (AML1/ETO)

• Acute myeloid leukaemia with abnormal BM eosinophils and inv(16)(q13;q22) or t(16;16)(p13;q22), (CBF&MYHU) (= FAB M4Eo)

• Acute promyelocytic leukaemia with t(15;17)(q22;q12), (PML/RARa) and variants (= FAB M3)

• Acute myeloid leukaemia with 11q23 (MLL) abnormalities

Acute myeloid leukaemia with multilineage dysplasia

• Following MDS or MDS/MPD

• Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of cells in 2 or more myeloid lineages

Acute myeloid leukaemia and myelodysplastic syndromes, therapy-related

• Alkylating agent/radiation-related type

• Topoisomerase II inhibitor-related type (some may be lymphoid)

Acute myeloid leukaemia, not otherwise categorised

Categorise as:

• Acute myeloid leukaemia, minimally differentiated (= FAB M0)

• Acute myeloid leukaemia, without maturation (= FAB M1)

• Acute myeloid leukaemia with maturation (= FAB M2)

• Acute myelomonocytic leukaemia (= FAB M4)

• Acute monoblastic/ acute monocytic leukaemia (= FAB M5a/5b)

• Acute erythroid leukaemia: erythroid/myeloid (> 50% erythroid precursors plus >20% blasts; = FAB M6) and pure erythroleukaemia (>80% immature erythroid precursors)

• Acute megakaryoblastic leukaemia (= FAB M7)

• Acute basophilic leukaemia

• Acute panmyelosis with myelofibrosis (= acute myelofibrosis)

• Myeloid sarcoma

0 0

Post a comment